Literature DB >> 2380030

Effect of zinc therapy on neutrophil chemotaxis in psoriasis.

V Leibovici1, M Statter, L Weinrauch, E Tzfoni, Y Matzner.   

Abstract

Neutrophil chemotaxis in patients with psoriasis vulgaris and psoriatic arthritis was investigated before and after 6 weeks of treatment with zinc sulphate (50 mg elementary zinc three times daily). In patients with active psoriasis vulgaris, a significant increase in neutrophil random migration and directed chemotaxis was demonstrated (10.2 +/- 3.1 and 14.1 +/- 4.1 mu, respectively, greater than that of control patients), while in patients with psoriatic arthritis the values were within the normal range (5.8 +/- 3.2 and 1.1 +/- 4.1 mu, respectively, greater than that of control patients). Although the zinc sulphate treatment had little or no effect on the course of either disease, it restored both the random migration and directed chemotaxis to normal values in psoriasis vulgaris patients. These results support the contention that zinc sulphate modifies neutrophil inflammatory potential; however, the lack of a clinical benefit suggests that neutrophils play only a secondary role in the pathogenesis of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2380030

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  3 in total

1.  Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis.

Authors:  D Biasi; A Carletto; P Caramaschi; P Bellavite; T Maleknia; C Scambi; N Favalli; L M Bambara
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

2.  Lack of classic histology should not prevent diagnosis of necrolytic acral erythema.

Authors:  Danette Bentley; Aleodor Andea; Aton Holzer; Boni Elewski
Journal:  J Am Acad Dermatol       Date:  2008-11-06       Impact factor: 11.527

3.  Dramatic response to oral zinc in a case of subacute form of generalized pustular psoriasis.

Authors:  Shikha Verma; Binod Kumar Thakur
Journal:  Indian J Dermatol       Date:  2012-07       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.